Fluoxetine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Using the drug repurposing report template to generate the Fluoxetine evaluation report from the supplied Evidence Pack.
Fluoxetine: From Major Depressive Disorder to Schizoid Personality Disorder
One-Sentence Summary
Fluoxetine (DrugBank DB00472) is a selective serotonin reuptake inhibitor (SSRI); within this evidence pack it is referenced repeatedly as an established therapy for major depressive disorder and panic disorder. The TxGNN model’s top-ranked prediction points to Schizoid Personality Disorder, but currently 0 clinical trials and only 3 tangentially related publications support this direction, none of which tested fluoxetine as a treatment for the condition.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in India regulatory data (drug unmarketed); evidence-pack rationale identifies fluoxetine as an SSRI approved for Major Depressive Disorder and Panic Disorder |
| Predicted New Indication | Schizoid Personality Disorder |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known information within this evidence pack, fluoxetine is an SSRI whose efficacy in major depressive disorder and panic disorder is well established, and the underlying hypothesis is that serotonergic modulation could extend to broader psychiatric conditions, including personality disorders.
However, the direct link to schizoid personality disorder is weak. Per the evidence pack’s own rationale: the three retrieved publications were not designed to test fluoxetine’s efficacy for schizoid personality disorder — they instead mention schizoid-type personality traits only as a comorbid finding within studies of body dysmorphic disorder and depression treatment course. There is no treatment-outcome or mechanistic data specific to schizoid personality disorder.
Given the absence of any clinical trial and the indirect nature of the available literature, the mechanistic connection should be regarded as a knowledge-graph association rather than a substantiated pharmacological hypothesis at this time.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29955451 | 2016 | Review | The Mental Health Clinician | Reviews pharmacologic treatment options for Cluster A personality disorders (paranoid, schizoid, schizotypal); notes the evidence base for pharmacotherapy in this group is limited. |
| 10929788 | 2000 | Cross-sectional descriptive study | Comprehensive Psychiatry | Assessed personality traits/disorders (including schizoid traits) in patients with body dysmorphic disorder; not a treatment study for schizoid PD. |
| 16390895 | 2006 | Cohort | The American Journal of Psychiatry | 6-month depression treatment outcome study examining personality traits as predictors of illness course; schizoid PD not a treatment target. |
Safety Considerations
Drug Interactions: DDI screening returned 360 total documented interactions for fluoxetine. Major-severity interactions identified in the sample include:
- Bupropion (Major)
- Lorcaserin (Major)
- Diethylpropion (Major)
- Dolasetron (Major)
- Eliglustat (Major)
- Palonosetron (Major)
- Cisapride (Major)
Additional Moderate-level interactions (e.g., Famotidine, Loperamide, Morphine, Acetylsalicylic acid, Clarithromycin) are on file; full review of the DDI database is recommended prior to any prescribing decision. Key warnings and contraindications from the local product label are not yet available (Blocking data gap — see Next Steps).
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is supported only by indirect, comorbidity-focused literature with no clinical trials and no treatment-outcome data specific to schizoid personality disorder; combined with missing TFDA-equivalent safety labeling and MOA data, there is currently insufficient basis to advance this candidate.
To proceed, the following is needed:
- TFDA (or equivalent) label warnings/contraindications data — currently a Blocking gap
- Fluoxetine mechanism of action (MOA) data — currently a High-severity gap
- Treatment-focused studies (open-label or controlled) evaluating fluoxetine specifically in schizoid personality disorder populations
- Consideration of re-ranking review priority toward higher-evidence candidates in this same prediction set (e.g., melancholia: L1/S3; agoraphobia and phobic disorder: L2/S2), which show substantially stronger clinical trial and literature support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.